The estimated Net Worth of Marco Dolci is at least 1.07 百万$ dollars as of 30 March 2023. Mr. Dolci owns over 3,563 units of LivaNova PLC stock worth over 381,308$ and over the last 5 years he sold LIVN stock worth over 686,329$. In addition, he makes 0$ as Head of Global Operations and R&D at LivaNova PLC.
Sign up
Mr. Dolci LIVN stock SEC Form 4 insiders trading
Marco has made over 14 trades of the LivaNova PLC stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 3,563 units of LIVN stock worth 169,064$ on 30 March 2023.
The largest trade he's ever made was selling 8,278 units of LivaNova PLC stock on 18 May 2021 worth over 686,329$. On average, Marco trades about 2,428 units every 80 days since 2020. As of 30 March 2023 he still owns at least 8,036 units of LivaNova PLC stock.
You can see the complete history of Mr. Dolci stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Marco Dolci biography
Marco Dolci serves as Head of Global Operations and R&D of the Company. Marco Dolci joined LivaNova in March 2017 as President, Europe and subsequently became President, Europe and Head of Global Manufacturing Operations (December 2018 to January 2020) and has been in his current role as Head of Global Operations and R&D since January 2020. Prior to joining the Company, Mr. Dolci was with Danaher Corporation as its Vice President of Danaher Business System?–?Dental Consumable Platform (April 2016 to March 2017); President of Global Digital Dentistry (November 2014 to April 2016); President?–?Dental Consumable Platform?–?EMEA, Asia and Pacific Region (December 2012 to December 2014); and President, Kerr EMEA (October 2010 to December 2012). Prior to his tenure at Danaher, Mr. Dolci served as President and CEO, EMEA for Hitachi Medical System Europe Holding AG. Earlier in his career, he worked in various positions at Eastman Kodak S.A.?–?Health Care Division, GE Healthcare and Philips Medical Systems. Mr. Dolci holds a master’s degree in nuclear physics from University of Milan and an Executive M.B.A. from Polytechnic University of Milan.
How old is Marco Dolci?
Marco Dolci is 58, he's been the Head of Global Operations and R&D of LivaNova PLC since 2020. There are 9 older and 11 younger executives at LivaNova PLC. The oldest executive at LivaNova PLC is Arthur Rosenthal, 73, who is the Independent Director.
What's Marco Dolci's mailing address?
Marco's mailing address filed with the SEC is 20 EASTBOURNE TERRACE, , LONDON, X0, W26LG.
Insiders trading at LivaNova PLC
Over the last 9 years, insiders at LivaNova PLC have traded over 79,802,010$ worth of LivaNova PLC stock and bought 4,000 units worth 268,530$ . The most active insiders traders include William A Kozy、Two S.C.A.Tower 6 S. A R.L....、Peter M Wilver. On average, LivaNova PLC executives and independent directors trade stock every 10 days with the average trade being worth of 315,922$. The most recent stock trade was executed by Peter M Wilver on 15 June 2024, trading 2,680 units of LIVN stock currently worth 127,166$.
What does LivaNova PLC do?
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
What does LivaNova PLC's logo look like?
Complete history of Mr. Dolci stock trades at LivaNova PLC
LivaNova PLC executives and stock owners
LivaNova PLC executives and other stock owners filed with the SEC include:
-
Damien McDonald,
Chief Executive Officer, Director -
Keyna Skeffington,
Senior Vice President, General Counsel and Company Secretary -
Alistair Simpson,
Special Advisor -
Edward Andrle,
Special Advisor -
Damien McDonald,
CEO & Director -
Keyna Pidcock Skeffington,
Sr. VP, Gen. Counsel & Corp. Sec. -
Alex Shvartsburg,
CFO and Corp. VP of Financial Planning, Analysis & International Region -
Daniel Moore,
Independent Chairman of the Board -
Hugh Morrison,
Independent Director -
Alfred Novak,
Independent Director -
Francesco Bianchi,
Independent Director -
Arthur Rosenthal,
Independent Director -
Andrea Saia,
Independent Director -
Sharon O'Kane,
Independent Director -
William Kozy,
Independent Director -
Stacy Seng,
Independent Director -
Marco Dolci,
Head of Global Operations and R&D -
Roy Khoury,
President - International, Senior Vice President - Global Strategic Marketing -
Trui Hebbelinck,
Chief Human Resource Officer -
Alex Shvartsburg,
Interim Chief Financial Officer -
Stephanie Bolton,
Pres of International Region -
Paul R. Buckman,
Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement -
Dr. Bryan D. Olin Ph.D.,
Sr. VP & Head of Product Devel. - Neuromodulation -
Trui Hebbelinck,
Chief HR Officer -
Matthew Joseph Dodds III,
Sr. VP of Corp. Devel. -
Deanna Wilke,
Director of Corp. Communications -
Lullo Stefano Di,
Pres Cardiac Rhythm Mgmt -
Michel Darnaud,
President Cardiac Surgery -
Thad Allen Huston,
Chief Financial Officer -
Vivid Sehgal,
CFO -
Two S.C.A.Tower 6 S. A R.L....,
-
Jacques Gutedel,
President Intercontinental -
Stefano Gianotti,
Director -
Piero Vecchi,
VP & Controller -
Pritpal Shinmar,
SR VP Global Market Access -
Robert Jason Richey,
President, Neuromodulation -
Douglas John Manko,
Chief Accounting Officer -
David S Wise,
SR VP HR & IT -
Todd C Schermerhorn,
Director -
Ahmet Tezel,
Chief Innovation Officer -
Brian Sheridan,
SR VP Genl Counsel & Secretary -
Andre Michel Ballester,
CEO -
Demetrio Mauro,
Chief Integration Officer -
James Christopher Barry,
Director -
Peter M Wilver,
Director -
Brooke Story,
Director -
Michael Damon Hutchinson,
Chief Legal Officer -
Stephanie Bolton,
President, Global Epilepsy -
Vladimir Makatsaria,
Chief Executive Officer